The U.S. NIAID (National Institute of Allergy and Infectious Diseases) has claimed that AstraZeneca provided incomplete and outdated efficacy data from latest COVID-19 trial.
AstraZeneca said a day earlier that its Covid-19 vaccines developed with Oxford university was 79% effective in preventing symptomatic illness in large trial in the US, Peru and Chile.
However, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) claimed that AstraZeneca may have provided incomp...
